While the results of combinatorial therapeutic strategies with retinoids in patients with breast cancer have been generally disappointing [165], retinoids have been shown to inhibit the expansion of chemoresistant cytokeratin 5-positive (CK5+) cells through RAR/PR crosstalk [166]. Here, PGR is linked to breast carcinoma.